BioMedical Technology Solutions (BMTL.OB) Posts 107% Revenue Growth

BioMedical Technology Solutions Holdings, Inc. reported its third quarter financial results as well as the 9-month

BioMedical Technology Solutions (BMTS.OB)

BioMedical Technology Solutions (BMTL.OB)

period ended September 30, 2010 through a 10Q filed with the Security and Exchange Commission. BMTL is a provider of safe and environmentally sound medical waste disposal equipment for sharps and red bag waste that allows for medical waste to be processed, sterilized, labeled and then disposed of as common trash. The Company operates through its wholly-owned subsidiary, BioMedical Technology Solutions (“BMTS”). As with most developing companies, the company is operating at a loss, but there were many significant improvements in this most recent quarter as compared to the same period in 2009.

Most notably, revenues for the third quarter in 2010 were $238,298 as compared to $115,019 in 2009, an increase of 107%. The management of BMTS attributes these gains to successful sales campaigns that have been launched through its distributors. Throughout the year, BMTS signed multiple distribution agreements, both domestically and internationally, that have been added to an ever-growing list of distributors which includes industry giant, Henry Schein. Through these distributors, the company’s Demolizer® II units are now found in medical, dental, veterinary, nursing, assisted living, and other health care facilities, including facilities that are properties of, or controlled by, organizations such as the U.S. Department of Veterans Affairs and U.S. HealthWorks.

BioMedical Technology Solutions also reported significant decreases in operating expenses for the third quarter. Selling, general and administrative costs for the quarter totaled $313,119 as compared to $503,624 for the year prior quarter, reflecting a 37.83% decrease. BMTS effected many cost-cutting measures in 2009, with the exception of stock based compensation, to promote the decrease in expenses. Additionally, research and development costs were lowered by nearly 60% from $55,793 in the third quarter of 2009 to $22,367 in the same quarter of 2010 as a result of further cost-cutting tactics.

While still operating at a net loss, the net loss was markedly lowered by 57%. Net losses for the third quarter of 2009 were $530,202. In the same quarter this year, net losses were $230,829.

For most small cap companies, operating at a loss is inevitable for several years while business strategies are fully intact and realized through ongoing expansions in distribution and sales. BioMedical Technology Solutions is in this realm, but appears to be heading in the right direction. From prior press releases, it can be deduced that further announcements of Demolizer® II sales with U.S. HealthWorks are to be coming in the fourth quarter, which will keep investors on the lookout for a possible strong quarter to end the year.

The complete SEC filing can be found on

More information on BioMedical Technology Solutions and its technologies can be found on the Company’s website at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Tactical Air Defense Services Buying Air 1 Flight Support

Tactical Air Defense Services Buying Air 1 Flight Support(0)

Tactical Air Defense Services, Inc. (Pinksheets: TADF) said Friday morning that it has signed a Letter of Intent to acquire 100 percent of Air 1 Flight Support, Inc. a privately-held provider of aircraft maintenance, refueling and support services headquartered in Denison, Texas, in an all-stock transaction. Tactical Air Defense Services is certified by the U.S.

Electronic Control Security Lands Prime Government Contract

Electronic Control Security Lands Prime Government Contract(0)

Shares of Electronic Control Security, Inc. (OTCBB: EKCS) have soared ahead in Friday morning trading after the company said that it has received a prime contract award from the Department of the Navy, Space and Naval Warfare Systems Center Atlantic (SPAWAR). The Clifton, New Jersey-based provider of integrated entry control and perimeter security systems said

Brightcove Shares Nosedive on Weak 2013 Guidance

Brightcove Shares Nosedive on Weak 2013 Guidance(0)

Coming up on its one-year anniversary of being a public entity, shares of Brightcove, Inc. (NASDAQ: BCOV) printed all-time lows after delivering its fourth-quarter and full 2012 year earnings and a weak outlook for 2013. The provider of cloud-based video streaming services reported total revenue for the fourth quarter of 2012 of $24.3 million, an

Balqon Lithium Battery System Installed in Hybrid Yacht

Balqon Lithium Battery System Installed in Hybrid Yacht(0)

Investors are used to hearing about lithium battery technologies for use in automobiles, but Balqon Corporation (OTCBB: BLQN) is taking them from the street to the water. On Friday, the Harbor City, California-based developer of electric vehicles, drive systems and lithium battery storage systems said that it has delivered and installed its HIQAP high energy

NCAL Bancorp and Grandpoint Capital Terminate Merger Agreement

NCAL Bancorp and Grandpoint Capital Terminate Merger Agreement(0)

NCAL Bancorp (OTCQB: NCAL) and Grandpoint Capital, Inc. said in a joint announcement Tuesday that the two companies have terminated their definitive agreement to merge. Under the agreement, which was entered into in June 2012, Grandpoint was to acquire NCAL Bancorp and its subsidiary National Bank of California. Los Angeles, California-based NCAL and Bank of

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.